HC Wainwright & Co. Initiates Coverage On Halozyme Therapeutics with Buy Rating, Announces Price Target of $61
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Mitchell Kapoor has initiated coverage on Halozyme Therapeutics (NASDAQ:HALO) with a Buy rating and a price target of $61.
July 24, 2023 | 10:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics has been given a Buy rating by HC Wainwright & Co. with a price target of $61.
The Buy rating and price target of $61 by HC Wainwright & Co. indicates a positive outlook for Halozyme Therapeutics. This could potentially attract investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100